Products

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bovine TNF receptor superfamily member 13C (TNFRSF13C) ELISA Kit-Sandwich

Name: Bovine TNF receptor superfamily member 13C (TNFRSF13C) ELISA Kit-Sandwich
SKU: EK10F83
Rating: 5 (1 reviews)

Cat. No.EK10F83

Product TypeAnimal Immunoassay Kits

Size

Inquiry Now Add to Basket

Product Overview

BioVenic Bovine TNFRSF13C ELISA Kit-Sandwich is designed for the quantitative determination of Bovine TNF receptor superfamily member 13C (TNFRSF13C) in serum, plasma, tissue homogenate, cell culture supernatant, cell lysate, and other biological fluids using a Sandwich ELISA method. For research use only.

Specifications

Assay Type ELISA-Sandwich

Specificity The assay kit is specific for Bovine TNFRSF13C.

Target Species Bovine

Species Reactivity Bovine

Detection Range 80-5000 pg/mL

Sensitivity 15.6 pg/mL

Reproducibility Intra-Assay: CV < 10%; Inter-Assay: CV < 10%

Assay Time Around 180 min

Sample Requirement Serum, plasma, tissue homogenate, cell culture supernatant, cell lysate, and other biological fluids.

Target Information

TNF receptor superfamily member 13C is encoded by the TNFRSF13C gene in cattle. It is a key regulator of the proliferation, development, and maturation of B cells

Target/Biomarker Bovine TNFRSF13C

Target Synonym TNF receptor superfamily member 13C

Gene ID 618516

UniProt ID F1MJD0

Shipping and Storage

This product is shipped with gel ice packs. It is recommended to store at 2-8 °C (Up to 6 months).

Documents

Datasheet

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

References

Huang, W. et al. Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer. Scientific reports. 2023, 13: 789.